This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.89% per year. These returns cover a period from January 1, 1988 through March 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
moving-average-crossover: Archive
CI&T (CINT) Surges 6.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
CI&T (CINT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CINTPositive Net Change VERXNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Strength Seen in Okta (OKTA): Can Its 7.4% Jump Turn into More Strength?
by Zacks Equity Research
Okta (OKTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
OKTANegative Net Change FTNTNegative Net Change
momentum-stocks moving-average-crossover price-performance stock-price-movement stocks-moving-today
Affirm Holdings (AFRM) Recently Broke Out Above the 50-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?
AFRMNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Hims & Hers Health (HIMS) Stock Jumps 23.0%: Will It Continue to Soar?
by Zacks Equity Research
Hims & Hers Health (HIMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
HIMSNegative Net Change HCATNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Eldorado Gold Corporation (EGO) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
EGOPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
CG Oncology, Inc. (CGON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CGONNo Net Change QUREPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last?
by Zacks Equity Research
Urogen Pharma (URGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
URGNPositive Net Change LQDAPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
StoneCo Ltd. (STNE)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
STNENegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Klaviyo, Inc. (KVYO) Surges 10.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Klaviyo, Inc. (KVYO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
KVYOPositive Net Change AIPNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last?
by Zacks Equity Research
Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
RYTMNegative Net Change MIRMPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
SpringWorks Therapeutics (SWTX) Soars 9.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
SpringWorks Therapeutics (SWTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
SWTXPositive Net Change PHARPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
ProDex (PDEX) Moves 5.1% Higher: Will This Strength Last?
by Zacks Equity Research
ProDex (PDEX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
PDEXNegative Net Change XRAYNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Strength Seen in Piedmont Lithium (PLL): Can Its 24.6% Jump Turn into More Strength?
by Zacks Equity Research
Piedmont Lithium (PLL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
PLLNegative Net Change HBMNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Should You Buy Regulus (RGLS) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
RGLSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Radware (RDWR) Soars 5.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Radware (RDWR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
RDWRPositive Net Change FSLYNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Lundin (LUNMF) Moves 6.4% Higher: Will This Strength Last?
by Zacks Equity Research
Lundin (LUNMF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
LUNMFNegative Net Change ERONegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Novavax (NVAX) Surges 19.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
NVAXPositive Net Change BNTXPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Journey Medical (DERM) Moves 16.8% Higher: Will This Strength Last?
by Zacks Equity Research
Journey Medical (DERM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
DERMNegative Net Change CATXPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Forge Global (FRGE) Surges 41.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
Forge Global (FRGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
FRGENegative Net Change RITMPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
GBank Financial Holdings Inc. (GBFH) Surges 7.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
GBank Financial Holdings Inc. (GBFH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
GBFHNo Net Change FFWMPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Stoke Therapeutics (STOK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
STOKPositive Net Change XOMANegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Fidelity National (FIS) Moves 8.7% Higher: Will This Strength Last?
by Zacks Equity Research
Fidelity National (FIS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
FISPositive Net Change GPNNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Bausch (BHC) Moves 13.3% Higher: Will This Strength Last?
by Zacks Equity Research
Bausch (BHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
BHCNegative Net Change RDYNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?
by Zacks Equity Research
uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
QUREPositive Net Change KNSAPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
FitLife Brands (FTLF) Surges 13.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
FitLife Brands (FTLF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
FTLFNegative Net Change LMATNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today